Literature DB >> 34116011

Outcomes of a Modified Treatment Ladder Algorithm Using Retrobulbar Amphotericin B for Invasive Fungal Rhino-Orbital Sinusitis.

Davin C Ashraf1, Oluwatobi O Idowu1, Kristin E Hirabayashi1, Evan Kalin-Hajdu2, Seanna R Grob1, Bryan J Winn1, M Reza Vagefi1, Robert C Kersten3.   

Abstract

PURPOSE: To assess whether a modified treatment ladder algorithm incorporating transcutaneous retrobulbar amphotericin B (TRAMB) for invasive fungal rhino-orbital sinusitis can reduce the risk of exenteration without compromising survival.
DESIGN: Retrospective, comparative clinical study with historical control subjects.
METHODS: Fifty consecutive patients with biopsy-proven invasive fungal sinusitis and radiographic evidence of orbital involvement were evaluated at a single tertiary institution from 1999-2020. TRAMB was incorporated as part of the treatment algorithm in 2015. Demographics, underlying immune derangement, infective organism, ophthalmic examination, surgical care, and survival were compared in a quasiexperimental pre-post format, dividing patients into a pre-2015 group and a post-2015 group. Risk of exenteration and mortality were the primary outcomes.
RESULTS: Baseline characteristics did not differ significantly between the 2 groups. Nearly all patients underwent a surgical intervention, most commonly functional endoscopic sinus surgery with debridement. TRAMB was administered to 72.7% of the post-2015 group. Exenteration was more common in the pre-2015 group (36.4% vs 9.1% [95% confidence interval {CI} 5.2-48.8]; P = .014), while mortality was similar (40.0% vs 36.7% [95% CI -22.1 to 29.3]; P = .816). After adjusting for potential confounders, patients treated after 2015 were found to have lower risk of exenteration (relative risk 0.28 [95% CI 0.08-0.99]; P = .049) and similar risk of mortality (relative risk 1.04 [95% CI 0.50-2.16]; P = .919).
CONCLUSION: Compared with historical control subjects, patients with invasive fungal rhino-orbital sinusitis who were treated with a modified treatment ladder algorithm incorporating TRAMB had a lower risk of disfiguring exenteration without an apparent increase in the risk of mortality. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34116011     DOI: 10.1016/j.ajo.2021.05.025

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

1.  Commentary: COVID-19-associated mucormycosis: The ongoing battle.

Authors:  Akshay Gopinathan Nair
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

2.  COVID-19-associated mucormycosis: Preliminary report from a tertiary eye care centre.

Authors:  Shweta Walia; Vijay Bhaisare; Preeti Rawat; Neetu Kori; Manushree Sharma; Niti Gupta; Shishir Urdhwareshwar; Sanchiyka Thakur; Niharika Arya
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

3.  Initial and ongoing challenges with COVID-19-associated mucormycosis.

Authors:  Kapil Sikka; Gaurav Goel; Namrata Sharma; Alok Thakar
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

4.  Chronic invasive fungal sinusitis with orbital and olfactory cleft involvement secondary to indolent mucormycosis.

Authors:  Aaron R Kaufman; Alex B Labby; Chau Pham; Gursant S Atwal; Tatiana K Dixon; Burce Ozgen Mocan; Victoria S Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-18

5.  Transcutaneous retrobulbar amphotericin-B (TRAMB) injection in orbital mucormycosis.

Authors:  Prabhakar Singh; Abhishek Gupta; Sravani Reddy Sanepalli; Amit Raj
Journal:  BMJ Case Rep       Date:  2022-03-31

6.  Clinico-Radiological-Pathological Correlation of Visual Loss in COVID-Associated Rhino-Orbito-Cerebral Mucormycosis.

Authors:  Ruchi Goel; Ritu Arora; Shalin Shah; Mohit Chhabra; Jyoti Kumar; Nita Khurana; Swati Gupta; Samreen Khanam; Sumit Kumar; Sonam Singh; Ravi Meher; Meenakshi Thakar; Anju Garg
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2022-05-11       Impact factor: 2.011

7.  Commentary: Data and COVID-19-associated mucormycosis: Time to pause and reassess?

Authors:  Akshay Gopinathan Nair
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

8.  Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience.

Authors:  Lakshmi B Ramamurthy; Ridhi Bhandari; Savitha Kanakpur; P Thejaswini
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

9.  Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India.

Authors:  Himanshu Yadav; Snigdha Sen; Tirupati Nath; Shefali Mazumdar; Anu Jain; Pinky Verma; Preeti Gupta
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

10.  Outcomes of Transcutaneous Retrobulbar Amphotericin B in Rhino-Orbital-Cerebral Mucormycosis Among Patients Recovering From COVID-19: A Preliminary Experience.

Authors:  Shivani Sinha; Vidya B Kumar; Abhay Kumar; Vivek Singh; Abhishek Anand; Rakhi Kusumesh; Sarita Mishra; Pragati Raj; Bibhuti P Sinha
Journal:  Cureus       Date:  2022-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.